Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin-induced diabetes in mice

Basit Öğe Kaydı
dc.authoridTekin, Suat/0000-0002-2757-1802
dc.authoridULKER ERTUGRUL, Nazife/0000-0002-3805-2362
dc.authoridOzcan, Mete/0000-0002-5551-4880
dc.authoridTektemur, Ahmet/0000-0002-2476-0413
dc.authorwosidTektemur, Ahmet/V-8755-2018
dc.authorwosidOzcan, Sibel/V-9471-2018
dc.authorwosidTekin, Suat/KEI-2266-2024
dc.authorwosidTekin, Suat/IZD-9868-2023
dc.authorwosidSerhatlioglu, Ihsan/V-9821-2018
dc.authorwosidTekin, Suat/AAG-1440-2021
dc.authorwosidKelestimur, Haluk/V-9392-2018
dc.contributor.authorOzcan, Mete
dc.contributor.authorCanpolat, Sinan
dc.contributor.authorBulmus, Ozgur
dc.contributor.authorUlker, Nazife
dc.contributor.authorTektemur, Ahmet
dc.contributor.authorTekin, Suat
dc.contributor.authorOzcan, Sibel
dc.date.accessioned2024-08-04T20:45:27Z
dc.date.available2024-08-04T20:45:27Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe main objective of this study was to investigate potential effectiveness of agomelatine pretreatment in the prevention of diabetes itself and encephalopathy, with a focus on brain tissue oxidative stress and inflammatory processes in streptozotocin (STZ)-induced diabetic mice. Interleukine-1 beta (IL-1 beta) and TACR1 (NK1), which is a tachykinine receptor, were used for the investigation of inflammation in the brain regions including raphe nucleus, periaqueductal gyrus (PAG), amygdala, and nucleus accumbens. The effects of agomelatine on total antioxidant capacity were also evaluated. In the in vitro part of the study, the effects of agomelatine on cell viability were investigated in dorsal root ganglion (DRG) neurons. Fasting blood glucose levels were measured 72 h after STZ injection to determine the diabetic condition. Agomelatine pretreatment prevented both hyperglycemia and hypoinsulinemia in STZ-treated mice. When STZ was injected to induce diabetes in mice, neither hyperglycemia nor hypoinsulinemia was developed in agomelatine pretreated mice and 6 weeks after development of diabetes, agomelatine treatment significantly decreased levels of IL-1 beta mRNA in raphe nucleus and nucleus accumbens. TACR1 mRNA levels were lower in raphe nucleus, PAG, and amygdala of agomelatine-treated diabetic mice. The increase in total antioxidant capacity after agomelatine administration may responsible for its beneficial effect in the prevention of diabetes. We showed that agomelatine reversed high glucose-induced cell viability decreases in DRG neurons. Both the antihyperglycemic and antioxidant effects of agomelatine might have contributed to the DRG neuron viability improvement. In conclusion, agomelatine seems to both prevent development of diabetes and reverse the encephalopathic changes caused by diabetes.en_US
dc.description.sponsorshipTurkish Scientific Technical Research Organization (TUBITAK) [115S290]en_US
dc.description.sponsorshipThis work was supported by Turkish Scientific Technical Research Organization (TUBITAK Project No: 115S290).en_US
dc.identifier.doi10.1111/fcp.12413
dc.identifier.endpage180en_US
dc.identifier.issn0767-3981
dc.identifier.issn1472-8206
dc.identifier.issue2en_US
dc.identifier.pmid30216538en_US
dc.identifier.scopus2-s2.0-85054569216en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage170en_US
dc.identifier.urihttps://doi.org/10.1111/fcp.12413
dc.identifier.urihttps://hdl.handle.net/11616/98488
dc.identifier.volume33en_US
dc.identifier.wosWOS:000460954300004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofFundamental & Clinical Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectagomelatineen_US
dc.subjectantioxidant capacityen_US
dc.subjectcell viabilityen_US
dc.subjectdiabetesen_US
dc.subjectmelatonergic (MT1 and MT2) receptorsen_US
dc.subjectserotonergic (5-HT2C) receptoren_US
dc.titleAgomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin-induced diabetes in miceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu